The Cancer Epigenetics Society is very excited to announce the appointment of Dr. Cheryl H. Arrowsmith to the Editorial Board of Cancer Epigenetics journals series.
Dr. Arrowsmith holds the Canada Chair in Structural Genomics and is Chief Scientist of the Structural Genomics Consortium (SGC) Toronto laboratories. Dr. Arrowsmith is also Professor of Medical Biophysics at the University of Toronto and Senior Scientist at the Ontario Cancer Institute and Princess Margaret Cancer Center. Together with Aled Edwards and Jack Greenblatt, Dr. Arrowsmith also founded Affinium Pharmaceuticals, a structure-guided drug discovery Biotech company.
Dr. Arrowsmith is a Fellow of the American Association for the Advancement of Science (AAAS) and is Editor of Cell Chemical Biology (Cell Press). Her current research is centered on the structural and chemical biology of epigenetics. She is a recognized expert in histone methyltransferase-mediated epigenetics, in the structural determinants of histone PTMs recognition by readers, writers, and erasers. She is also a major contributor and coordinator of the SGC structure-guided epigenetic chemical probe program, whereby she uses chemical probes to map epigenetic vulnerabilities in cancer that can be exploited for individualized cancer therapy.
The Cancer Epigenetics Society is looking forward to working with Dr. Cheryl Arrowsmith in establishing the highest possible standards in structural epigenetics and chemical probe research published in the Cancer Epigenetics Society journals (Cancer Epigenetics Society news; May 3, 2017).